A security analysis is not yet prepared for this market.
The series is stated in the current share scale after splits; dividends are not included in the price
Roivant buys shelved drugs from large companies and takes them to approval through separate subsidiaries.
A large pharmaceutical company often shelves a promising molecule not because it is bad but because the market is small by its standards. Roivant buys such programmes cheaply and builds a separate company around each, with its own team motivated by that one drug's outcome.
The model has been proved by sales: one subsidiary holding a drug for inflammatory bowel disease was sold to a large pharmaceutical company for a sum that changed the whole group's position. Hence a large cash balance and funding for the remaining programmes without issuing shares. Risks: trial outcomes and the certainty that some programmes will not reach the market. The company pays no dividend.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Roivant Sciences Ltd. (ROIV) is a company in the Health care sector; its shares trade on Nasdaq.
The price of Roivant Sciences Ltd. (ROIV) on November 16, 2026 is $38.61, −2.33% on the day. Over 52 weeks the stock traded between $19.96 and $42.50; the price now sits 83% of the way up that range. Over the past year the price changed by +90.29%. Market capitalisation is $27.90 billion, rank 13 among 381 stocks of the same industry with a known capitalisation.
Roivant Sciences Ltd. trades on Nasdaq under the ticker ROIV. The company belongs to the Health care sector. The trading history on this page starts on 8 December 2020.
Over the past 52 weeks ROIV has traded between $19.96 and $42.50. As of 16 November 2026 the price stood 82.74% of the way from the 52-week low to the high.
Over one year ROIV shares rose 90.29%; over six months they rose 35.24%. Volatility over 90 days is 48.36%. Dividends are not included: this is price change only, as of 16 November 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 3,704, above the sector median of 3.6. Price to book is 6.6, above the sector median of 2.3. Calculated from reports for the period ending 30 June 2026.
ROIV has a return on equity of −6.29%, above the sector median of −40.58%. Return on assets is −5.02%, above the sector median of −30.08%.